A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Rosa Álvarez-Álvarez, Alejandro García‐Álvarez, Thomas Walter, David Taïeb et al.
Citations
3 citations
Journal
BMC Cancer
Topics
Neuroendocrine Tumor Research Advances
Field-Weighted Citation Impact (FWCI)
4.06
article
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Rosa Álvarez-Álvarez, Alejandro García‐Álvarez, Thomas Walter, David Taïeb, Nicola Fazio, Sara Cingarlini, J.C. Ruffinelli, Guillermo Villacampa, Côme Lepage, Magalie Haissaguerre, Jorge Hernando, Javier Molina‐Cerrillo, Francesco Panzuto, Paula Jiménez‐Fonseca, Amparo García-Burillo, Rocio García‐Carbonero, Sergio Baldari, Frank Aboubakar Nana, Maddalena Sansovini, María Isabel Del Olmo-García, Alice Durand, Timon Vandamme, Virginia Pubul, Teresa Alonso‐Gordoa, Urbano Anido, Emmanuel Deshayes, María San Román, Angelina Filice, Catherine Ansquer, Marta Benavent Viñuales, Eric Baudin, Laurence Lousberg, Jaume Capdevila, Amandine Béron, B. Fdez Llana
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
Université Claude Bernard Lyon 1 (FR), University of Messina (IT), Universidad Complutense de Madrid (ES), Hebron University (PS), Cliniques Universitaires Saint-Luc (BE), University of Antwerp (BE), Université de Bordeaux (FR), Inserm (FR), Universitat de València (ES), Université de Bourgogne (FR), Universidade de Santiago de Compostela (ES), Aix-Marseille Université (FR), Institut Gustave Roussy (FR), Hospital General Universitario Gregorio Marañón (ES), Centre Hospitalier Universitaire de Lille (FR), Hospital Universitari i Politècnic La Fe (ES), Centre Hospitalier Universitaire de Nantes (FR), Bureau Veritas (France) (FR), Research Institute Hospital 12 de Octubre (ES), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR), Complejo Hospitalario Universitario de Santiago (ES), Hospices Civils de Lyon (FR), Hospital Universitario 12 De Octubre (ES), Antwerp University Hospital (BE), Vall d'Hebron Institut de Recerca (ES), Institut Català d'Oncologia (ES), Laboratoire de Thermique et Energie de Nantes (FR), Center for Research in Molecular Medicine and Chronic Diseases (ES), Hôpital Edouard Herriot (FR), Centre de Recherche en Cancérologie de Lyon (FR), Institut de Médecine Tropicale du Service de Santé des Armées (FR), Instituto de Biomedicina de Sevilla (ES), Hospital Universitario Central de Asturias (ES), Centre de recherche Translationnelle en Médecine moléculaire (FR), Institut de Recherche en Cancérologie de Montpellier (FR), Hôpital Claude Huriez (FR), Hospital Universitario Ramón y Cajal (ES), Vall d'Hebron Institute of Oncology (ES), European Institute of Oncology (IT), Sapienza University of Rome (IT), UCLouvain (BE), Nantes Université (FR)